FDA Approves Caplyta by Intra-Cellular Therapies to Treat Schizophrenia

published 10:30 pm ET December 23rd, 2019

On December 23, Intra-Cellular Therapies, Inc. (ITCI) announced that it received FDA approval of drug CAPLYTA®(lumateperone) for the treatment of schizophrenia in adults. Schizophrenia is a serious mental illness impacting approximately 2.4 million adults in the United States. The company expects to launch CAPLYTA® by the end of the first quarter in 2020.

 

Jet Equities sent an alert to subscribers at 6:59 am. The last trade was at 7:59 pm the previous day for $12.39. The next trade took place at 7:00 am for $15.13. The stock price surged after the announcement and closed at $36.51 for an event-day gain of 141%.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

Subscribe here if you would like to start receiving these signals in real-time and start trading!